At the last check on Friday, AcelRx Pharmaceuticals Inc.’s (NASDAQ:ACRX) stock was up $0.08, moving up 9.54 percent to $0.92. The average number of shares traded per day over the past five days has been 721,886 shares. 2 times new highs have been achieved over the past 5 days, with a $0.0549 gain in that time frame. In the last twenty days, the average volume was 236,101, while in the previous 50 days, it was 178,211.
Since last month, ACRX stock retreated -14.02%. Shares of the company fell to $0.7500 on 08/15/23, the lowest level in the past month. A 52-week high of $7.17 was reached on 01/13/23 after having rallying from a 52-week low of $0.55. Since the beginning of this year, ACRX’s stock price has dropped by -59.29% or -$1.3250, and marked a new high 3 times. However, the stock has declined by -87.17% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Right now, AcelRx Pharmaceuticals Inc. (ACRX) has a P/E ratio of about 0.14. The stock’s beta is 0.28. Besides these, the trailing price-to-sales (P/S) ratio of 5.69, the price-to-book (PB) ratio of 0.70.
Financial Health
On the profitability front, the trailing twelve-month gross margin is 47.40% percent. Based on annual data, ACRX earned -$0.82 million in gross profit and brought in $1.77 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -132.80%. Return on equity (ROE) for the past 12 months was 175.60%.
ACRX’s revenue fell -128.0% during the quarter, while net income inched up to $0.25 million. While analysts expected AcelRx Pharmaceuticals Inc. to report -$0.53 quarterly earnings, the actual figure was -$0.4 per share, beating the consensus estimate by 24.50%. During the quarter, the company generated -$3.92 million in EBITDA. The liabilities of AcelRx Pharmaceuticals Inc. were 7.31 million at the end of its most recent quarter ended June 29. The value of shareholders’ equity is $16.34 million.
Technical Picture
This quick technical analysis looks at AcelRx Pharmaceuticals Inc.’s (ACRX) price momentum. With a historical volatility rate of 125.90%, the RSI 9-day stood at 52.49% on 17 August.
With respect to its five-day moving average, the current AcelRx Pharmaceuticals Inc. price is up by +6.24% percent or $0.0549. At present, ACRX shares trade -8.33% below its 20-day simple moving average and +23.35% percent above its 100-day simple moving average. However, the stock is currently trading approximately -14.22% below its SMA50 and -64.58% below its SMA200.
Stochastic coefficient K was 34.99% and Stochastic coefficient D was 20.04%, while ATR was 0.0895. Given the Stochastic reading of 59.68% for the 14-day period, the RSI (14) reading has been calculated as 47.86%.
Analyst Ratings
AcelRx Pharmaceuticals Inc. downgraded its rating on AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX) to an Underperform in a note to investors on July 20, 2020. The analysts firm previously had a Neutral rating on the stock.
